Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/14/22
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic DermatitisPRNewsWire • 06/07/22
Regeneron Gets Wall Street-Low Price Target. The Stock May Be Done Outperforming the Market.Barrons • 06/06/22
Regeneron (REGN) Down 1.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/03/22
Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaborationMarket Watch • 06/02/22
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of CancerPRNewsWire • 06/02/22
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone PaymentGlobeNewsWire • 06/02/22
Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularisGlobeNewsWire • 05/31/22
FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo NodularisPRNewsWire • 05/31/22
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)Zacks Investment Research • 05/25/22